Answer
Nivolumab monotherapy has a geometric mean terminal half-life of 25.0 days at 3 mg/kg every 2 weeks, based on a population pharmacokinetic analysis.
Sources for this answer
- OPDIVO 10 mg/mL concentrate for solution for infusionBristol Myers Squibb Pharmaceuticals limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 70Document updated
Sources checked